A panelist discusses how immune thrombocytopenia (ITP) is characterized by isolated low platelet counts due to autoimmune destruction, with classification based on duration (acute, extended, or ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune pathophysiology of immune thrombocytopenia (ITP) by modulating B cells, ...
Immune thrombocytopenia (ITP) is an autoimmune disease in which IgG antiplatelet antibodies accelerate platelet clearance and reduce platelet production. The prevalence of ITP is approximately 1 to 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback